Literature DB >> 25341373

Positron emission tomographic imaging of CXCR4 in cancer: challenges and promises.

Guillaume Pierre Charles George, Federica Pisaneschi, Quang-Dé Nguyen, Eric Ofori Aboagye.   

Abstract

Molecular imaging is an attractive platform for noninvasive detection and assessment of cancer. In recent years, the targeted imaging of the C-X-C chemokine receptor 4 (CXCR4), a chemokine receptor that has been associated with tumor metastasis, has become an area of intensive research. This review article focuses on positron emission tomography (PET) and aims to provide useful and critical insights into the application of PET to characterize CXCR4 expression, including the chemical, radiosynthetic, and biological requirements for PET radiotracers. This discussion is informed by a summary of the different approaches taken so far and a comparison of their clinical translation. Finally, our expert opinions as to potential future advances in the field are expressed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25341373     DOI: 10.2310/7290.2014.00041

Source DB:  PubMed          Journal:  Mol Imaging        ISSN: 1535-3508            Impact factor:   4.488


  10 in total

1.  A benzenesulfonamide derivative as a novel PET radioligand for CXCR4.

Authors:  Yoon Hyeun Oum; Dinesh Shetty; Younghyoun Yoon; Zhongxing Liang; Ronald J Voll; Mark M Goodman; Hyunsuk Shim
Journal:  Bioorg Med Chem       Date:  2019-11-30       Impact factor: 3.641

Review 2.  Radiotheranostics in Cancer Diagnosis and Management.

Authors:  Hossein Jadvar; Xiaoyuan Chen; Weibo Cai; Umar Mahmood
Journal:  Radiology       Date:  2018-02       Impact factor: 11.105

Review 3.  Artificial Intelligence and the Future of Diagnostic and Therapeutic Radiopharmaceutical Development:: In Silico Smart Molecular Design.

Authors:  Bahar Ataeinia; Pedram Heidari
Journal:  PET Clin       Date:  2021-08-05

4.  [177Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent.

Authors:  Margret Schottelius; Theresa Osl; Andreas Poschenrieder; Frauke Hoffmann; Seval Beykan; Heribert Hänscheid; Andreas Schirbel; Andreas K Buck; Saskia Kropf; Markus Schwaiger; Ulrich Keller; Michael Lassmann; Hans-Jürgen Wester
Journal:  Theranostics       Date:  2017-06-11       Impact factor: 11.556

Review 5.  Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases.

Authors:  Helen Ha; Bikash Debnath; Nouri Neamati
Journal:  Theranostics       Date:  2017-04-07       Impact factor: 11.556

6.  [64Cu]NOTA-pentixather enables high resolution PET imaging of CXCR4 expression in a preclinical lymphoma model.

Authors:  Andreas Poschenrieder; Margret Schottelius; Theresa Osl; Markus Schwaiger; Hans-Jürgen Wester
Journal:  EJNMMI Radiopharm Chem       Date:  2017-01-19

7.  A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.

Authors:  Theresa Osl; Alexander Schmidt; Markus Schwaiger; Margret Schottelius; Hans-Jürgen Wester
Journal:  Theranostics       Date:  2020-07-09       Impact factor: 11.556

8.  Impact of the Chemokine Receptors CXCR4 and CXCR7 on Clinical Outcome in Adrenocortical Carcinoma.

Authors:  Irina Chifu; Britta Heinze; Carmina T Fuss; Katharina Lang; Matthias Kroiss; Stefan Kircher; Cristina L Ronchi; Barbara Altieri; Andreas Schirbel; Martin Fassnacht; Stefanie Hahner
Journal:  Front Endocrinol (Lausanne)       Date:  2020-11-13       Impact factor: 5.555

9.  Automated Radiosynthesis, Quality Control, and Biodistribution of Ga-68 Pentixafor: First Indian Experience.

Authors:  Ankit Watts; Surbhi Chutani; Diksha Arora; Vasanth Madivanane; Samiksha Thakur; Monika Kamboj; Baljinder Singh
Journal:  Indian J Nucl Med       Date:  2021-09-23

10.  Preclinical evaluation of [(68)Ga]NOTA-pentixafor for PET imaging of CXCR4 expression in vivo - a comparison to [(68)Ga]pentixafor.

Authors:  Andreas Poschenrieder; Margret Schottelius; Markus Schwaiger; Hans-Jürgen Wester
Journal:  EJNMMI Res       Date:  2016-09-21       Impact factor: 3.138

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.